A Phase 3, Open-Label, Multicenter, Randomized Study of SKLB1028 Versus Salvage Chemotherapy in Patients With FLT3-mutated Acute Myeloid Leukemia Refractory to or Relapsed After First-line Treatment ALIVE
Latest Information Update: 09 Nov 2021
At a glance
- Drugs SKLB 1028 (Primary) ; Aclarubicin; Azacitidine; Azacitidine; Cytarabine; Fludarabine; Granulocyte colony-stimulating factors; Granulocyte colony-stimulating factors; Omacetaxine mepesuccinate
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms ALIVE
- Sponsors CSPC ZhongQi Pharmaceutical Technology
- 01 Nov 2021 Status changed from not yet recruiting to recruiting.
- 21 Jan 2021 New trial record